CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody (mABs) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion
CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by MarketsandMarkets. The monoclonal antibody therapeutics market is primarily driven by factors such as increasing prevalence of chronic diseases like cancer, autoimmune disorders, and infectious diseases.
Based on therapy area the monoclonal antibody therapeutics market is segmented into autoimmune & inflammatory disorders, oncology, hematology, opthalmology and other therapy area. In 2023, autoimmune & inflammatory diseases segment dominated the monoclonal antibody therapeutics market. The monoclonal antibody therapeutics market for autoimmune and inflammatory diseases and cancer is driven by several factors.
Key players in the monoclonal antibody therapeutics market are F. Hoffmann-La Roche Ltd , Abbvie Inc. , Johnson & Johnson Services, Inc. , Merck & Co., Inc. , Bristol Myers Squibb Company , AstraZeneca , Sanofi , Novartis AG , Amgen Inc. , Takeda Pharmaceutical Company Limited , GSK plc. , Eli Lilly and Company , Regeneron Pharmaceuticals Inc. , and among others.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.